Nanolek to produce Sanofi meningococcal vaccine in Russia

Russian drugmaker Nanolek says it will start the production of French pharma major Sanofi’s (Euronext: SAN) meningococcal vaccine in Russia, with the aim of its further sales through state tenders. The annual production volume will reach 3.5 million doses.

An agreement between Nanolek and Sanofi on the localization of packaging and quality control of Menactra meningococcal vaccine at a plant in the Kirov region was signed on October 4.

So far, the Nanolek production site has already received a registration certificate for the drug. Sanofi announced that it plans to produce 2.2-3.5 million doses of Menaсtra at the partner's site annually. According to the general manager of Sanofi Pasteur for the Eurasian region, Frederic Jumel, this volume is sufficient to cover the existing demand for the vaccine. The partners did not disclose the volume of investments in the project.